Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Beijing InnoCare Pharma Tech Co., Ltd."
Count: 35
Selected: 0
NCT IDTitle
NCT05702268Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
NCT05690581Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects With Advanced Solid Tumors
NCT05688696Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
NCT05684653Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
NCT05232149A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
NCT05678270A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05372120A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
NCT04492293An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
NCT04685226A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT05660720Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
NCT05367232A Study of ICP-033 in Patients With Advanced Solid Tumors
NCT05234684A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
NCT04305197A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
NCT05451199A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
NCT04304040A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
NCT05051891A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
NCT04440059A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
NCT04438044A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
NCT03797456A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
NCT05552937Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04014205A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
NCT04438005A Study of ICP-022 in Patients With R/R DLBCL
NCT05399030A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects
NCT05316857DDI Study of Orelabrutinib
NCT03758664Clinical Study of ICP-192 in Solid Tumors Patients
NCT03642834Study of ICP-105 in Solid Tumors Patients
NCT03494179A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
NCT03493217A Study to Evaluate ICP-022 in Patients With CLL/ SLL
NCT04711148A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
NCT05370755A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
NCT04578613ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
NCT04565275A Study of ICP-192 in Patients With Advanced Solid Tumors
NCT05210868A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
NCT04441450ADME Study of [14C]ICP-022 in Healthy Males
NCT05284175A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder